From the State Council Joint Prevention and Control Mechanism Research Group on the 14th that China ’s two new inactivated coronavirus vaccines received the clinical trial license of the Phase I and II of the State Drug Administration and became the first New inactivated coronavirus vaccine for clinical research approval.
The two inactivated vaccines were developed by Sinopharm Group Wuhan Biological Products Research Institute and Beijing Kexing Zhongwei Biotechnology Co, Ltd. jointly with relevant scientific research institutions.
Inactivated vaccine is a vaccine that kills pathogenic microorganisms but still maintains its immunogenicity.
It has the advantages of mature production technology, controllable quality standards, and wide protection scope. China’s vaccine emergency research is currently proceeding in accordance with five technical routes: inactivated vaccines, recombinant protein vaccines, adenovirus vector vaccines, live attenuated influenza virus vector vaccines, and nucleic acid vaccines.
Prior to this, the adenovirus vector vaccine of the Academy of Military Medical Sciences of the Academy of Military Sciences has been approved for clinical trials.